Construct validity analysis. حسب Aistė Ambrasė (22505574)

الموضوعات:

Sociodemographic Characteristics of the final sample. حسب Aistė Ambrasė (22505574)

الموضوعات:

Results of Confirmatory Factor Analyses (N = 378). حسب Aistė Ambrasė (22505574)

الموضوعات:

Correlations between OUS-DE, its subscales and personality measurements in Sample 2. حسب Aistė Ambrasė (22505574)

الموضوعات:

English and German versions of OUS. حسب Aistė Ambrasė (22505574)

الموضوعات:

The mean parasite concentration in the excreted urine of <i>Trypanosoma cruzi</i>-infected <i>Rhodnius prolixus</i> maintained at (A) 26°C and (B) 28°C at different triatomine deve... حسب Henri Loshouarn (17896676)

Sampling process. حسب Mahée Gilbert-Ouimet (3665080)

"…For men patients, direct medical costs were $5351 [4649, 6053] and $4234 [2880, 5588] for women in the first year after the event, $221 [–229, 671] for men and $226 [–727, 1179] for women in the second year, and $11 [–356, 377] for men and $-24 [–612, 564] for women in the third year. This decrease was observed for both men and women, with higher costs for men. …"

Means ± SD of isolated lens surface parameters. حسب Ronald A. Schachar (16674576)

Synergy is not captured by low-dimensional manifolds. حسب Thomas F. Varley (8446899)

AL scores at baseline and follow-ups. حسب Eric Priedemann (21175492)

"…</p><p>Results</p><p>Average AL scores of men decreased, while women’s AL scores returned to baseline levels after an initial decrease observed at the first follow−up. …"

Participant recruitment process flowchart. حسب Azam Ildarabadi (20565175)

"…The risk of HDL-C appeared to decrease in the third quartile of pepper consumption (HR: 1, 0.97, 0.87, 1.03, P-trend = 0.008).…"

Participant recruitment process flowchart. حسب Azam Ildarabadi (20565175)

"…The risk of HDL-C appeared to decrease in the third quartile of pepper consumption (HR: 1, 0.97, 0.87, 1.03, P-trend = 0.008).…"

Table6_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx حسب J. Riera-Arnau (20431328)

"…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …"

Table4_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx حسب J. Riera-Arnau (20431328)

"…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …"

Table2_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx حسب J. Riera-Arnau (20431328)

"…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …"

Table8_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx حسب J. Riera-Arnau (20431328)

"…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …"

Table5_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx حسب J. Riera-Arnau (20431328)

"…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …"

Table3_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx حسب J. Riera-Arnau (20431328)

"…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …"

Table7_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx حسب J. Riera-Arnau (20431328)

"…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …"

Table1_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.DOCX حسب J. Riera-Arnau (20431328)

"…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …"